Pfizer’s Troxyca ER Opioid Combo Faces Intravenous Abuse Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
More oxycodone was extracted from the combination product, potentially defeating the opioid-blunting effects of the naltrexone component and creating a hurdle to an abuse-deterrent claim.